Intra-Cellular Therapies Inc
NASDAQ:ITCI

Watchlist Manager
Intra-Cellular Therapies Inc Logo
Intra-Cellular Therapies Inc
NASDAQ:ITCI
Watchlist
Price: 85.71 USD 2.04%
Market Cap: 9.1B USD
Have any thoughts about
Intra-Cellular Therapies Inc?
Write Note

Intra-Cellular Therapies Inc
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Intra-Cellular Therapies Inc
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Intra-Cellular Therapies Inc
NASDAQ:ITCI
Revenue
$613.7m
CAGR 3-Years
106%
CAGR 5-Years
N/A
CAGR 10-Years
85%
Johnson & Johnson
NYSE:JNJ
Revenue
$87.7B
CAGR 3-Years
-1%
CAGR 5-Years
1%
CAGR 10-Years
2%
Bristol-Myers Squibb Co
NYSE:BMY
Revenue
$47.4B
CAGR 3-Years
1%
CAGR 5-Years
14%
CAGR 10-Years
11%
Pfizer Inc
NYSE:PFE
Revenue
$60.1B
CAGR 3-Years
-4%
CAGR 5-Years
14%
CAGR 10-Years
2%
Merck & Co Inc
NYSE:MRK
Revenue
$63.2B
CAGR 3-Years
11%
CAGR 5-Years
7%
CAGR 10-Years
4%
Eli Lilly and Co
NYSE:LLY
Revenue
$40.9B
CAGR 3-Years
14%
CAGR 5-Years
13%
CAGR 10-Years
7%
No Stocks Found

Intra-Cellular Therapies Inc
Revenue Breakdown

Breakdown by Geography
Intra-Cellular Therapies Inc

Not Available

Breakdown by Segments
Intra-Cellular Therapies Inc

Total Revenue: 464.4m USD
100%
Product Sales, Net: 462.2m USD
99.5%
Grant Revenue: 2.2m USD
0.5%

Intra-Cellular Therapies Inc
Glance View

Market Cap
9.1B USD
Industry
Pharmaceuticals
Economic Moat
Narrow

Intra-Cellular Therapies Inc., founded in 2002, finds itself at the intersection of scientific innovation and commercial success. This biopharmaceutical company is built around the vision of translating ground-breaking discoveries in neuroscience into important medications for serious neuropsychiatric and neurological disorders. The firm’s flagship product, CAPLYTA (lumateperone), exemplifies its dedication to comprehensive central nervous system solutions. Approved by the FDA for the treatment of schizophrenia in adults, and later approved for bipolar depression, CAPLYTA positions Intra-Cellular Therapies within a competitive landscape of mental health treatments. It is through pharmaceutical sales of CAPLYTA that Intra-Cellular Therapies generates revenue, capitalizing on extensive research to carve out a niche in a market with significant medical needs. Operating predominantly in the United States, Intra-Cellular Therapies harnesses its proprietary technologies, including PDE1 inhibition and other novel mechanisms of action, to pioneer treatments aimed at improving patients' quality of life. The company invests heavily in research and development, fueled by its robust clinical pipeline that constantly explores new therapeutic opportunities. Their approach involves not just the development of medications but also extensive engagement with healthcare providers and thought leaders to better understand and serve the patient community. This strategy underscores a business model where innovation directly translates to market viability, as the company embarks on long-term growth through the expansion of indications for its existing drugs and exploration of new compounds.

ITCI Intrinsic Value
64.7 USD
Overvaluation 25%
Intrinsic Value
Price

See Also

What is Intra-Cellular Therapies Inc's Revenue?
Revenue
613.7m USD

Based on the financial report for Sep 30, 2024, Intra-Cellular Therapies Inc's Revenue amounts to 613.7m USD.

What is Intra-Cellular Therapies Inc's Revenue growth rate?
Revenue CAGR 10Y
85%

Over the last year, the Revenue growth was 46%. The average annual Revenue growth rates for Intra-Cellular Therapies Inc have been 106% over the past three years , and 85% over the past ten years .

Back to Top